Myelosuppression is an important and potentially lethal complication of azathioprine treatment. The blood count has been reviewed in all patients treated with azathioprine for inflammatory bowel disease over 27 years in one hospital. Altogether 739 patients (422 with Crohn's disease, 284 with ulcerative colitis, and 33 with indeterminate colitis) were treated with 2 mg/kg/day azathioprine for a median of 12-5 months (range 0.5-132) between 1964 and 1991. Full blood counts were performed monthly for the duration of treatment. In 37 patients (5%) who developed bone marrow toxicity, the drug was withdrawn or the dose reduced. Thirty two of these patients were asymptomatic and five developed symptoms. Leucopenia (white blood count less than 3Oxl10s/1 ) occurred in 28 (3.8%) patients, in nine of whom it was severe (white blood count <2 Ox 109/l). Ofthese nine patients, three were pancytopenic: two died from sepsis and the other had pneumonia but recovered. A further two patients with severe leucopenia developed a mild upper respiratory infection only. Thrombocytopenia (platelet count <100 000 x 106/1) in 15 patients was associated with leucopenia in six and developed in isolation in a further nine (total 2%). Isolated thrombocytopenia was never clinically severe. Myelotoxicity from azathioprine developed at any time during drug treatment (range 2 weeks-li years after starting the drug) and occurred either suddenly or over several months. Bone marrow suppression as a result of azathioprine treatment is uncommon when a moderate dose is used, but is potentially severe. Leucopenia is the commonest and most important haematological complication. Regular monitoring of the full blood count is recommended during treatment.
W R Connell, M A Kamm, J K Ritchie, J E Lennard-Jones Abstract Myelosuppression is an important and potentially lethal complication of azathioprine treatment. The blood count has been reviewed in all patients treated with azathioprine for inflammatory bowel disease over 27 years in one hospital. Altogether 739 patients (422 with Crohn's disease, 284 with ulcerative colitis, and 33 with indeterminate colitis) were treated with 2 mg/kg/day azathioprine for a median of 12-5 months (range 0.5-132) between 1964 and 1991. Full blood counts were performed monthly for the duration of treatment. In 37 patients (5%) who developed bone marrow toxicity, the drug was withdrawn or the dose reduced. Thirty two of these patients were asymptomatic and five developed symptoms. Leucopenia (white blood count less than 3Oxl10s/1 ) occurred in 28 (3.8%) patients, in nine of whom it was severe (white blood count <2 Ox 109/l). Ofthese nine patients, three were pancytopenic: two died from sepsis and the other had pneumonia but recovered. A further two patients with severe leucopenia developed a mild upper respiratory infection only. Thrombocytopenia (platelet count <100 000 x 106/1) in 15 patients was associated with leucopenia in six and developed in isolation in a further nine (total 2%). Isolated thrombocytopenia was never clinically severe. Myelotoxicity from azathioprine developed at any time during drug treatment (range 2 weeks-li years after starting the drug) and occurred either suddenly or over several months. Bone marrow suppression as a result of azathioprine treatment is uncommon when a moderate dose is used, but is potentially severe. Leucopenia is the commonest and most important haematological complication. Regular monitoring of the full blood count is recommended during treatment. (Gut 1993; 34: 1081 -1085 Azathioprine is well established as an effective drug in the treatment of inflammatory bowel disease. Although its usefulness was not shown in four controlled studies of patients with active Crohn's disease or ulcerative colitis,A a further six controlled trials examining this drug or its metabolite, 6-mercaptopurine, in chronic active Crohn's disease and ulcerative colitis have shown steroid sparing effects in all subjects and a clear therapeutic advantage in most.s 10 Additional reports of uncontrolled studies support this impression. [11] [12] [13] [14] [15] [16] Concerns about the safety of azathioprine and 6-mercaptopurine, remain, however. Considerable clinical experience of azathioprine has now been obtained in organ transplantation, rheumatoid arthritis, and inflammatory bowel disease. The commonest sudden side effects include nausea, fever, pancreatitis, and bone marrow suppression."7 One large study of 1349 patients with a variety of immunological diseases not associated with transplant showed a slightly increased risk of neoplasia, but the extent to which the drug alone was responsible was uncertain. 18 The most common but potentially serious side effect is bone marrow suppression. The effect of azathioprine on bone marrow is largely dosedependent. A conventional immunosuppressive dose of less than 2 5 mg/k/day causes predictable macrocytosis, a raised mean corpuscular haemoglobin concentration, and mild leucopenia.'920 Rarely, sudden, severe, and unexpected myelosuppression, which is possibly idiosyncratic, has also been reported when low to moderate doses (<2 mg/kg/day) of the drug have been used.A22 This myelosuppression consists of severe leucopenia, thrombocytopenia, and sometimes pancytopenia.
In a retrospective study of 396 patients with inflammatory bowel disease who were treated with 6-mercaptopurine, 2% developed clinically severe leucopenia (white blood cell count <2 5 x 109/1). 7 
Discussion
Azathioprine is a synthetic analogue of the naturally occurring purine, adenosine. It is converted to 6-mercaptopurine and since their subsequent metabolism is identical, both drugs share similar clinical and side effects. The dose of 6-mercaptopurine required to produce equivalent therapeutic and toxic effects as azathioprine is about 55% that of azathioprine.23 These drugs possess both cytotoxic and immunosuppressive properties. Cytotoxicity is believed to result from the incorporation of thiopurine metabolites into cellular nucleic acids, while the immunosuppressive effects are secondary to inhibition of de novo purine ribonucleotide synthesis and interconversion. 24 Mild leucopenia, defined as a white cell count between 3 0 and 4 0x 109/l, is the commonest haematological side effect of azathioprine. This effect is thought to be dose-dependent and relates to a shift towards less mature forms and a decreased myeloid-erythroid ratio.'9 The principal effect of this drug on white blood cells is granulocytopenia, which occurs shortly after starting azathioprine. Accompanying bone marrow changes on granulopoiesis are not seen until the peripheral blood count falls below 2 0x 109/1.25 More profound bone marrow suppression occurs with higher doses ofazathioprine or can develop unexpectedly as an idiosyncratic reaction. In these cases, agranulocytosis or pancytopenia results from disturbed marrow cellularity and impaired cell line maturation. 25 The risk of leucopenia in inflammatory bowel disease as a result of azathioprine or 6-mercaptopurine treatment is reported to be 2 to 5%, though few studies define the term leucopenia clearly. 12 13 15-17 26 In the National Crohn's Disease Cooperative Study, 15% of patients treated with 2-5 mg/kg developed a white blood cell count less than 4 0x l09/1. In the same study, treatment with 1-0 mg/kg azathioprine was associated with a 2% incidence of leucopenia.27 In another study, 2% of 396 patients treated with 6-mercaptopurine in a dose of 1-5 mg/kg/day developed a white blood cell count ofless than 2-5x 109. '7 In a meta-analysis of 542 patients treated with azathioprine for rheumatoid arthritis, 14 patients (2 6%) developed a white blood count <2 5 x 109/1 and a further 34 patients (6 3%) developed a count of between 2-5 and 3-5x 109/1.26
Other effects of azathioprine are seen in the peripheral blood. Macrocytosis is common; it occurs in approximately 70% of renal transplant recipients.2829 Reversible erythroid hypoplasia has been reported in one patient given 6-mercaptopurine for Crohn's disease and four renal transplant recipients treated with azathioprine.'73 In keepting with our own findings, previous studies have shown that thrombocytopenia occurs less commonly than leucopenia and is not usually of clinical severity. 7 2631 To our knowledge five detailed case reports of pancytopenia related to the use of azathioprine for immunosuppression have been published. Four patients with connective tissue disease and one with ulcerative colitis developed reversible pancytopenia after 0-5-15 months of therapy with 75-100 mg/day azathioprine.2"2'32 Further reports of pancytopenia have been reported to the drug's manufacturers. '9 There has been only one reported death related to bone marow toxicity from immunosuppressive azathioprine treatment.33
The reasons for individual variation in bone marrow susceptibility to azathioprine deserve attention. Bone marrow toxicity seems to be related to the excessive intracellular concentration of the cytotoxic active metabolities 6-thioguanine nucleotides.2' These substances may accumulate if the activity of the catalytic enzyme thiopurine methyltransferase is deficient.
An inverse relationship between the red cell concentration of 6-thioguanine nucleotides and the neutrophil count has been reported in children given azathioprine for leukemia.34 Furthermore, five patients who developed acute myelosuppression after taking azathioprine at a dose of 1 0-2-5 mg/day showed very low thiopurine methyltransferase activities and abnormally high 6-thioguanine nucleotide concentrations compared with 16 patients who were also receiving azathioprine but did not have myelosuppression. 2 Further cases of patients with reduced thiopurine methyltransferase activity and leucopenia secondary to azathioprine or 6-mercaptopurine provide supporting evidence that low thiopurine methyltransferase activity may be a major risk factor for azathioprine induced myelosuppression.3 '36 The activity of thiopurine methyltransferase seems to be controlled by a common genetic polymorphism. One in 300 individuals in the population has very low or no enzyme activity and 11% have intermediate activity.37 Homozygotes and heterozygotes for this enzyme may have different thiopurine methyltransferase activity and therefore different susceptibility to azathioprine toxicity. The information on thiopurine methyltransferase and susceptibility to myelotoxicity from azathioprine is relatively recent, and post dates most of the data collected in this series. Testing for thiopurine methyltransferase activity is not routinely available at present, though it is possible to measure serum 6-thioguanine nucleotide concentrations.
Our experience with azathioprine in inflammatory bowel disease confirms that the risk of myelotoxicity is low but that this has potentially serious clinical sequelae. Leucopenia is the commonest and most serious toxic effect of azathioprine on the bone marrow. All five patients who developed symptoms related to bone marrow suppression were severely leucopenic. None of the patients with moderate leucopenia had symptoms. In other words, warning signs in the form of symptoms did not occur until myelosuppression was advanced.
Of the 37 patients with myelosuppression, 28 developed this complication within one month of a normal full blood count and the drug was stopped or its dose reduced. Twenty four of these patients were asymptomatic and it is not known how many would have gone on to develop more severe myelosuppression had the drug been continued at the same dose. Myelotoxicity was not recognised initially in the other nine patients and azathioprine was continued at the same dose; a progressive deterioration in the blood count occurred over the next month until the drug was stopped.
The deaths oftwo patients, after three and 132 months of azathioprine treatment, show that serious bone marrow toxicity is unpredictable. Complications affecting the bone marrow had a very variable time of onset after starting treatment in the other 35 patients with myelosuppression. Whilst reduced thiopurine methyltransferase activities may be responsible for azathioprine-induced myelotoxicity in some patients, the late onset of this complication in others suggests that additional factors must also be involved.
Both leucopenia and thrombocytopenia may recur with subsequent courses of azathioprine, particularly if the same dose is used; it is less likely to develop if dose reductions are made.
It seems prudent to stop the drug if moderate suppression of the white blood cell or platelet count occurs. We feel that azathioprine should never be used without blood tests; intervention only when symptoms occur may be too late. It could be argued that regular monitoring of the peripheral blood count did not influence the course of myelosuppression in our patients. In six ofthe nine patients with severe leucopenia the onset was sudden and unpredictable. This includes the two patients who died and the patient with pneumonia. However, the development of severe leucopenia could have been averted in the other three patients with more careful attention to the serial blood counts.
Routine blood testing throughout the duration of azathioprine treatment requires close and committed coordination between specialist, general practitioner, laboratory, and patient. An azathioprine card containing details of dose, possible side effects, and blood testing requirements should be given to patients taking this drug. The manufacturers of azathioprine recommend weekly blood testing for the first few months of treatment and three monthly or less thereafter. We believe that in inflammatory bowel disease where immunosuppressive doses of azathioprine are used, two weekly blood tests in the first three months of therapy are sufficient. Since the onset of myelosuppression is unpredictable, and often abrupt, we advocate more frequent testing of the blood count than three monthly for the remainder of treatment. 
